Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

NCT06319170 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia, Schizoaffective Disorder

Interventions

DRUG: Olanzapine Extended Release
DRUG: Olanzapine Immediate Release

Sponsor

Teva Branded Pharmaceutical Products R&D LLC